Medifast (MED) EBITDA (2010 - 2026)

Medifast's EBITDA history runs 17 years deep, the most recent figure standing at -$3.3 million for Q1 2026.

• Quarterly EBITDA fell 161.09% year-over-year to -$3.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$16.2 million (down 156.92% YoY) and the FY2025 annual result came in at -$14.2 million, down 593.85% from the prior year.
• EBITDA was -$3.3 million for Q1 2026 at Medifast, up from -$7.8 million in the prior quarter.
• Across five years, EBITDA topped out at $55.1 million in Q1 2022 and bottomed at -$7.9 million in Q2 2024.
• A 5-year average of $17.4 million and a median of $7.9 million in 2024 frame the typical range for EBITDA.
• Peak annual rise in EBITDA reached 86.47% in 2025, while the deepest fall reached 1200.56% in 2025.
• Medifast's EBITDA stood at $32.6 million in 2022, then plunged by 73.39% to $8.7 million in 2023, then sank by 91.83% to $709000.0 in 2024, then tumbled by 1200.56% to -$7.8 million in 2025, then surged by 57.77% to -$3.3 million in 2026.
• Business Quant data shows MED's EBITDA at -$3.3 million in Q1 2026, -$7.8 million in Q4 2025, and -$4.1 million in Q3 2025.